Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
Brief Summary: The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone


Options:
A: Arm Label: Saxagliptin and Metformin (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Metformin (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Placebo (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo, Drug: pioglitazone | Arm Label: Metformin and Placebo (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Placebo, Drug: pioglitazone | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (A), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B), Saxagliptin and Placebo (C)
B: Arm Label: Strategy A (Glucose-Dependent); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Pioglitazone, Drug: Acarbose, Drug: Linagliptin, Drug: Sitagliptin, Drug: Liraglutide, Drug: Exenatide once weekly (QW), Drug: Exenatide twice daily (BID) | Arm Label: Strategy B (Reference); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin, Drug: Pioglitazone, Drug: Acarbose, Drug: Linagliptin, Drug: Sitagliptin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Strategy B (Reference) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Acarbose; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Strategy A (Glucose-Dependent), Strategy B (Reference) | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Strategy A (Glucose-Dependent) | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Strategy B (Reference) | Intervention Type: DRUG; Name: Exenatide once weekly (QW); Assigned to Arm(s): Strategy A (Glucose-Dependent) | Intervention Type: DRUG; Name: Exenatide twice daily (BID); Assigned to Arm(s): Strategy A (Glucose-Dependent)
C: Arm Label: Dapagliflozin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Placebo for saxagliptin, Drug: Placebo for glimepiride | Arm Label: Dapagliflozin+saxagliptin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Saxagliptin, Drug: Placebo for glimepiride | Arm Label: Glimepiride+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo for dapagliflozin, Drug: Placebo for saxagliptin | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for dapagliflozin; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for saxagliptin; Assigned to Arm(s): Dapagliflozin+metformin, Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for glimepiride; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin
D: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo, Drug: metformin | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: liraglutide, Drug: metformin | Arm Label: Glim + Met; Type: EXPERIMENTAL; Interventions: Drug: glimepiride, Drug: metformin, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glim + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Glim + Met, Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glim + Met

Answer: A